From Yahoo Finance: 2025-04-02 01:32:00

Novo Holdings, the majority owner of Novo Nordisk, reported a record 8 billion euros in income and investment returns for 2024. The strong performance was driven by dividends from drugs like Wegovy and Ozempic. The company plans to expand in Asia and has increased its global staff to 205 employees.

In 2024, Novo Holdings saw a 18% return on its investment portfolio, up from 9.4% in 2023. The company invested 4.6 billion euros in life sciences, focusing on cancer, obesity, and neurodegenerative disorders. It acquired Catalent for $16.5 billion, selling three plants to Novo Nordisk for $11 billion to boost Wegovy production.

Despite the overall success, Novo Holdings’ total assets under management dropped slightly to 142 billion euros in 2024 due to a decline in Novo Nordisk’s market value. Novo Nordisk’s market value has decreased, in part, because of concerns about competition in the obesity drug market from U.S. rival Eli Lilly.



Read more at Yahoo Finance: Novo Holdings nearly doubles earnings as Wegovy swells coffers